Is "exploring alternative courses of action" to refinance the company after principal lender decides not to consummate refinancing plan, which had called for the lender to exchange $ 7 mil. worth of Duramed's secured indebtedness for 7,850,080 shares of Duramed stock. Alluding to market removal of Duramed's conjugated estrogen products, Duramed Chairman E. Thomas Arington blames "regulatory issues over the last two years" for the company's continued financial problems....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth